Literature DB >> 3905299

A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation.

N J Gonchoroff, P R Greipp, R A Kyle, J A Katzmann.   

Abstract

We describe a mouse monoclonal antibody (BU-1) reactive with 5-bromo-2-deoxyuridine (BrdUrd). The antibody is different from previously described BrdUrd monoclonal antibodies in that BU-1 does not require pretreatment of cells with strong DNA denaturants in order for the antibody to react with BrdUrd incorporated in the DNA. The antibody can be used in immunocytochemical and indirect immunofluorescent assays and can be used to identify cells that have incorporated BrdUrd. Double staining with BU-1 antibody and propidium iodide has been used to confirm S-phase measurements with the BU-1 antibody. Immunocytochemical stains using the BU-1 antibody do not destroy cell morphology and allow cell identification to be performed simultaneously with S-phase measurements. Flow cytometer two-color fluorescence analysis allows the simultaneous identification of cell surface or cytoplasmic markers and S-phase quantitation. The BU-1 antibody should broaden the application of cell kinetic measurements to individual elements of cell populations that are heterogeneous with respect to morphology, surface marker, and other biological features.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3905299     DOI: 10.1002/cyto.990060604

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  10 in total

1.  Bromodeoxyuridine (BrdU) immunocytochemistry by exonuclease III (Exo III) digestion.

Authors:  W N Dinjens; J ten Kate; M H Lenders; E P van der Linden; F T Bosman
Journal:  Histochemistry       Date:  1992-10

2.  Differentiation of intercalated cells in culture.

Authors:  G Fejes-Tóth; A Náray-Fejes-Tóth
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

3.  Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.

Authors:  R Bataille; M Jourdan; X G Zhang; B Klein
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

4.  Differential effects of CD45 CD45R and CD45R0 monoclonal antibodies in modulating human B cell activation.

Authors:  D L Deane; E Harvey; C M Steel
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

5.  The restoration of the functions of serially passaged calf hepatocytes by spheroid formation.

Authors:  F Karikusa; Y Sawasaki
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-01       Impact factor: 2.416

6.  Plasma cell proliferation in monoclonal gammopathies: measurement using BU-1 antibody in flow cytometry and microscopy: comparison with serum thymidine kinase.

Authors:  C M Schambeck; M Wick; R Bartl; R Lamerz; A Fateh-Moghadam
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

7.  ADAM8 is selectively up-regulated in endothelial cells and is associated with angiogenesis after spinal cord injury in adult mice.

Authors:  Edward T Mahoney; Richard L Benton; Melissa A Maddie; Scott R Whittemore; Theo Hagg
Journal:  J Comp Neurol       Date:  2009-01-10       Impact factor: 3.215

8.  Gene expression in oestrogen-dependent human breast cancer xenograft tumours.

Authors:  A M Thompson; C M Steel; M E Foster; D Kerr; D Paterson; D Deane; R A Hawkins; D C Carter; H J Evans
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

9.  Looking for ugly ducklings: The role of the stability of BrdU-antibody complex and the improved method of the detection of DNA replication.

Authors:  Anna Ligasová; Petr Konečný; Ivo Frydrych; Karel Koberna
Journal:  PLoS One       Date:  2017-03-30       Impact factor: 3.240

10.  T lymphocytes adhere to airway smooth muscle cells via integrins and CD44 and induce smooth muscle cell DNA synthesis.

Authors:  A L Lazaar; S M Albelda; J M Pilewski; B Brennan; E Puré; R A Panettieri
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.